Research Analysts Offer Predictions for ATXS FY2025 Earnings

Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Astria Therapeutics in a note issued to investors on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse expects that the biotechnology company will post earnings per share of ($1.98) for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Astria Therapeutics' current full-year earnings is ($1.65) per share.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.01.

Several other equities analysts have also issued reports on ATXS. Wedbush restated an "outperform" rating and set a $28.00 price target (up from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Citizens Jmp raised shares of Astria Therapeutics to a "strong-buy" rating in a research report on Friday, January 31st. Finally, JMP Securities began coverage on shares of Astria Therapeutics in a research note on Friday, January 31st. They set an "outperform" rating and a $26.00 price objective for the company. Five investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $30.00.

Astria Therapeutics Trading Down 13.3 %

Shares of NASDAQ:ATXS traded down $0.68 on Thursday, reaching $4.43. 247,339 shares of the company traded hands, compared to its average volume of 362,371. The stock has a market capitalization of $250.06 million, a P/E ratio of -2.12 and a beta of 0.45. The business's 50-day simple moving average is $5.38 and its 200 day simple moving average is $7.81. Astria Therapeutics has a 52 week low of $3.56 and a 52 week high of $12.92.

Hedge Funds Weigh In On Astria Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Barclays PLC grew its holdings in Astria Therapeutics by 70.5% in the third quarter. Barclays PLC now owns 92,651 shares of the biotechnology company's stock worth $1,020,000 after purchasing an additional 38,321 shares during the period. JPMorgan Chase & Co. boosted its holdings in Astria Therapeutics by 101.7% in the third quarter. JPMorgan Chase & Co. now owns 39,144 shares of the biotechnology company's stock worth $431,000 after acquiring an additional 19,735 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Astria Therapeutics by 51.3% in the fourth quarter. SG Americas Securities LLC now owns 21,296 shares of the biotechnology company's stock worth $190,000 after acquiring an additional 7,218 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Astria Therapeutics during the fourth quarter valued at $107,000. Finally, Rhumbline Advisers raised its position in shares of Astria Therapeutics by 2.3% in the 4th quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company's stock worth $556,000 after purchasing an additional 1,381 shares during the last quarter. Hedge funds and other institutional investors own 98.98% of the company's stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.